Millennium Management’s Viking Therapeutics VKTX Stock Holding History

Millennium Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.46M	Sell	75,700 -74,300	-50%	-$2.39M	﹤0.01%	3667
2025 Q4	$5.28M	Sell	150,000 -54,600	-27%	-$1.93M	﹤0.01%	2947
2025 Q3	$5.38M	Buy	204,600 +56,400	+38%	+$1.68M	﹤0.01%	3070
2025 Q2	$3.93M	Sell	148,200 -56,800	-28%	-$1.5M	﹤0.01%	3237
2025 Q1	$4.95M	Buy	205,000 +41,600	+25%	+$1.31M	﹤0.01%	2878
2024 Q4	$6.58M	Buy	163,400 +153,400	+1,534%	+$8.75M	﹤0.01%	2578
2024 Q3	$633K	Sell	10,000 -61,600	-86%	-$3.61M	﹤0.01%	4639
2024 Q2	$3.8M	Buy	71,600 +61,400	+602%	+$4.02M	﹤0.01%	2978
2024 Q1	$836K	Buy	+10,200	New	+$454K	﹤0.01%	4454
2023 Q4	–	Sell	-114,400	Closed	-$1.27M	–	6586
2023 Q3	$1.27M	Sell	114,400 -8,600	-7%	-$123K	﹤0.01%	3993
2023 Q2	$1.99M	Sell	123,000 -212,300	-63%	-$4.45M	﹤0.01%	3486
2023 Q1	$5.58M	Sell	335,300 -111,400	-25%	-$1.15M	﹤0.01%	2508
2022 Q4	$4.2M	Buy	+446,700	New	+$1.99M	﹤0.01%	2962

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management's VKTX Position: Q1 2026 in Review

Millennium Management increased its Viking Therapeutics (VKTX) stake by 192% in Q1 2026, buying an estimated $5.29M and bringing the position to 250,525 shares worth $8.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

Millennium Management first reported a position in VKTX in Q4 2017 and has held it in 29 quarters since. The position peaked at $63.9M in Q1 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Millennium Management held 250,525 shares of Viking Therapeutics worth $8.15M as of Q1 2026.
Millennium Management bought 164,724 Viking Therapeutics shares in Q1 2026, an estimated $5.29M.
Viking Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2378 holding.
Millennium Management first reported a position in Viking Therapeutics in Q4 2017 and has held it in 29 quarters since.
Millennium Management's Viking Therapeutics position peaked at $63.9M in Q1 2023.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.